Item 4 of the Schedule 13D is hereby supplemented by adding the following: On October 1, 2025, the Issuer filed the Schedule 13E-3 with the SEC, which included a preliminary proxy statement relating to the extraordinary general meeting of the Issuer's shareholders, at which the Issuer's shareholders will consider and vote upon, among other things, a proposal to authorize and approve the Merger Agreement and the transactions contemplated thereby (the "Proxy Statement"). According to the Proxy Statement, the Special Committee determined that the Competing Proposal would fail to constitute a "Superior Proposal" under the Merger Agreement and that the Issuer should proceed with the transactions contemplated by the Merger Agreement. The Reporting Persons believe that the Special Committee's determination is wrong and ill-made. Even accepting the Special Committee's view that the super-voting power held by management members would essentially foreclose the possibility of any "Superior Proposal", the Special Committee did not address why the Issuer must be taken private by the Consortium and why the Issuer should not continue to be a public company. On more than one occasion, the Reporting Persons brought to the attention of the Special Committee that the Issuer's ADSs have been trading above US$1.25 every single day since August 15, 2025 and pointedly asked the Special Committee to elaborate why it believed a sale of the Issuer to insiders at a price below the stock trading price and below the Issuer's cash amount (based on the Issuer's SEC filings) is in the best interest of public shareholders. The Special Committee never answered. In addition, the Proxy Statement reveals critical deficiencies and suspicious facts in the evaluation, negotiation and deliberation of the January Proposal and the Merger Agreement. A few examples: (i) the Proxy Statement indicated no price negotiation whatsoever between the Special Committee and the Consortium before entering into the Merger Agreement, despite the Special Committee's full awareness of the Reporting Persons grave concerns over the Consortium's offer price; (ii) the Special Committee interviewed only one legal counsel, Skadden, Arps, Slate, Meagher & Flom LLP ("Skadden"), and one financial advisor, Kroll, LLC ("Duff & Phelps"), before retaining them, raising the question of whether the selection of advisors had been preordained; (iii) Skadden is the Issuer's long-term legal counsel, calling its independence into question; (iv) Duff & Phelps provided an ADS valuation range of US$1.23 to US$1.29 - a narrow and precise band that aligns perfectly with the Current Price of US$1.25; and (v) the Proxy Statement contained no discussion of the consistently higher ADS trading prices nor did it address the Reporting Persons' repeated question as to why the Issuer and its shareholders' interests would be better served by a going-private transaction at US$1.25, rather than by maintaining the Issuer's public company status. As the January Proposal, the Merger Agreement and the contemplated going-private transactions substantially undervalue the Issuer and in light of the deficient negotiation and evaluation process, the Reporting Persons urge the Special Committee to act in the interests of unaffiliated shareholders to terminate the Merger Agreement and the contemplated transactions, and to maintain the Issuer as a public company. The Reporting Persons intend to continuously review their investment in the Issuer, and, notwithstanding anything contained herein, the Reporting Persons specifically reserve the right to change their intention with respect to any or all of such matters. The Reporting Persons and their affiliates may in the future take such actions with respect to its investment in the Issuer as it deems appropriate, including, without limitation, exchanging information with the Issuer or other third parties; proposing changes in the Issuer's operations, management, board of directors, governance or capitalization; acquiring additional securities of the Issuer or disposing of some or all of the securities beneficially owned by it, in public market or privately negotiated transactions; entering into financial instruments or other agreements that increase or decrease the economic exposure of the Reporting Persons with respect to their investment in the Issuer and/or otherwise changing the Reporting Persons' (or their affiliates') intention with respect to any and all matters referred to in Item 4 of Schedule 13D.